chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Post-injection inflammatory reaction. Redness, inflammation, and warm skin at injection site. Some pain/discomfort and inflammation that started the day after the injection and got worse over the next 2 days. There also appears to be a rash along the left arm that goes up to the shoulder.
Systemic: Dizziness / Lightheadness-Severe, Systemic: Exhaustion / Lethargy-Severe, Systemic: Fainting / Unresponsive-Severe, Systemic: Weakness-Severe
CHILD WAS SENT BACK TO THE CLINIC WITH REDDNESS AND ITCHING FROM TOP OF SHOULDER TO ELBOW ON THE ARM WHERE SHE GOT THE INJECTION.  BENADRYL WAS ADMINISTERED BY SCHOOL NURSE PER SCHOOL POLICY
Extreme soreness In arm and shoulder Loss of range of motion In arm, trouble sleeping, pain on waking up severe  Went to regular Dr who did xray which didnt show any broken bones Referred to Specialist. Dr who had MRI done which showed signs of Sirva. Then assigned 4 weeks of physical therapy there at 3x week. Then went back to Dr who assigned 3 more weeks of physican therapy 2 x week. I go back to Dr on June 13/2022. I feel like I have my range of motion back but strength I will need to work on at home.
Pt. is G1 P0000, EDD: 2/25/2018 and was seen today in clinic. She  was given a flu vaccine on 10/11/2017 and, in error, she was given the vaccine again today, on 1/24/2018.
warmth; itchy at injection site; swollen; redness; injection site rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (warmth), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE SWELLING (swollen), VACCINATION SITE ERYTHEMA (redness) and INJECTION SITE RASH (injection site rash) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included AMITRIPTYLINE, BUPROPION, ATENOLOL, EMPAGLIFLOZIN (JARDIANCE), ATORVASTATIN, SEMAGLUTIDE (OZEMPIC), METFORMIN and TRAZODONE for an unknown indication.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (warmth), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE SWELLING (swollen), VACCINATION SITE ERYTHEMA (redness) and INJECTION SITE RASH (injection site rash). The patient was treated with PREDNISONE for Rash, at a dose of 1 dosage form. At the time of the report, VACCINATION SITE WARMTH (warmth), VACCINATION SITE PRURITUS (itchy at injection site), VACCINATION SITE SWELLING (swollen) and VACCINATION SITE ERYTHEMA (redness) outcome was unknown and INJECTION SITE RASH (injection site rash) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was provided    Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Added a new event Rash and its treatment medication.
PATIENT REPORTED ACHINESS AND SWEATS THE EVENING OF THE VACCINE AND LOWER LIP SWELLING THE FOLLOWING MORNING.
Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE (SYNJARDY), LISINOPRIL, ROPINIROLE, GABAPENTIN, PRAVASTATIN and NAPROXEN (NAPROSYN E) for an unknown indication.    On 20-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced DIZZINESS (Dizziness). At the time of the report, DIZZINESS (Dizziness) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
The event was that the Moderna vaccine given on the second dose instead of the Pfizer. Pt did not have his card and was asked which vaccine he had had. He said Moderna. I took his word and gave hime Moderna.
2AUG95 rash began on face, chest, stomach & back;eyes became red & clear runny nose;rash spread to legs, feet, arms & butt & lasted 4-5 days;red eyes lasted 4 days as did runny nose;highest fever was 102.5 on 2AUG95
headache; dizziness that is very bizzare; like having hypoglycemia; very tender and very painful; swollen; red, swollen, very tender and very painful; super sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (super sore), DIZZINESS (dizziness that is very bizzare), HYPOGLYCAEMIA (like having hypoglycemia), INJECTION SITE PAIN (very tender and very painful) and HEADACHE (headache) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced PAIN IN EXTREMITY (super sore). On 15-Jan-2021, the patient experienced INJECTION SITE PAIN (very tender and very painful), INJECTION SITE SWELLING (swollen) and INJECTION SITE ERYTHEMA (red, swollen, very tender and very painful). On 04-Feb-2021, the patient experienced DIZZINESS (dizziness that is very bizzare) and HYPOGLYCAEMIA (like having hypoglycemia). On an unknown date, the patient experienced HEADACHE (headache). At the time of the report, PAIN IN EXTREMITY (super sore), DIZZINESS (dizziness that is very bizzare), HYPOGLYCAEMIA (like having hypoglycemia), INJECTION SITE PAIN (very tender and very painful), HEADACHE (headache), INJECTION SITE SWELLING (swollen) and INJECTION SITE ERYTHEMA (red, swollen, very tender and very painful) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product include Exedrin OTC.  Treatment details include that the patient may have taken Naproxen 400mg and applied heat.
Dizziness, nausea, vomiting and diarrhea with headaches. On Feb. 20, 2010 received intravenous fluids in Emergency Room.
This spontaneous report was received from a nurse refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant medications were not reported. On an unknown date from 17-NOV2016 to 15-DEC-2016, unspecified number of patients were vaccinated with improperly stored GARDASIL 9 (lot # M023169 and expiry date 13-JUN-2018) for prophylaxis. The vaccines were exposed to a temperature of 2.5 C for 1 hour and 10 mins. No adverse effects were reported. The call was because of digital data logger. There was no previous exposure. This is one of the several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1612USA013518: US-009507513-1612USA013519: US-009507513-1612USA013517: US-009507513-1612USA013520.
Sore arm after first dose; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PAIN (Sore arm after first dose) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On an unknown date, the patient experienced VACCINATION SITE PAIN (Sore arm after first dose). At the time of the report, VACCINATION SITE PAIN (Sore arm after first dose) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant products were reported.  No treatment information was reported by the reporter.  Patient took second dose and third dose on 12 Feb 2021 and 13 Oct 2021 respectively.   This case was linked to MOD-2021-352994, MOD-2021-352996, MOD-2021-352613, MOD-2021-352622, MOD-2021-352623 (Patient Link).
Information has been received from a female patient, a physician, who on 31-MAY-2007 was vaccinated with a "single dose" of Zostavax (Oka/Merck) (lot# 656609/0015U).  On 02-JUN-2007 the patient broke out in chicken pox.  The chicken pox resolved on 02-Jul-2007.  On an unspecified date, sometime after the chickenpox, it is reported that the patient experienced post herpetic neuralgia.  Unspecified medical attention was sought.  At the time of the report, the outcome of post herpetic neuralgia is reported as not recovered. No product quality complaint was involved.  Additional information has been requested.
This spontaneous report as received from a healthcare worker refers to unknown number of patients of unknown age. The unknown number of patients had received ZOSTAVAX (lot number not provided) and VARIVAX (Merck) (Lot number not provided) doses which were exposed to -6.8C for 1.5 hours every 24 hours due to defrost cycle every day. No adverse effect reported. It was unspecified if the patients had sought medical attention. The health care professional contacted during telephone follow-up did not remember which patient might have received these vaccines and could not supply the following information: patient name, date of birth, dates of vaccination, or lot number. She also stated that the vaccines have been moved to a proper storage unit. Follow-up information received from the healthcare worker. Patient information was updated. On 20-AUG-2013 the patient was vaccinated with a dose of improperly stored ZOSTAVAX (lot #, expiration date and route not reported). This report is one of the several reports received from the same source. Additional information has been requested.
No side effects; he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial; he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial; This spontaneous case was reported by a patient family member or friend and describes the occurrence of WRONG PRODUCT ADMINISTERED (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial), UNDERDOSE (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial) and NO ADVERSE EVENT (No side effects) in a 6-month-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     The patient received other vaccines in the 4 weeks prior to COVID-19 vaccine.  Previously administered products included for Product used for unknown indication: PCV13 and DTap-HepB-IPV. Past adverse reactions to the above products included No adverse event with DTap-HepB-IPV and PCV13.    On 07-Jul-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .2 milliliter. On 07-Jul-2023, the patient experienced WRONG PRODUCT ADMINISTERED (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial) and UNDERDOSE (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial). On an unknown date, the patient experienced NO ADVERSE EVENT (No side effects). At the time of the report, WRONG PRODUCT ADMINISTERED (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial), UNDERDOSE (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial) and NO ADVERSE EVENT (No side effects) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No side effects) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial) and UNDERDOSE (he received his initial Moderna bivalent dose today 7Jul2023 and his pediatrician gave him .2 ml from a the maroon cap vial).    No concomitant medication was reported. No side effect was reported. No treatment medication was reported.
Patient began experiencing flu like symptoms such as fever, chills, body aches (normal side effects) within a few hours but 2 days later began experiencing chest pain "like something heavy was weighing down on her chest". It subsided within 24 hours but then she felt the same thing again during lifting objects at work on 7/15/2021. It has since resolved and has not occurred again.
I tested positive for COVID-19. I had a deep cough; nauseas; diarrhea; terrible headache;  and weak. I was in bed for the first week. Called my doctor prescribed me Paxlovid. On week 8 still having a symptoms.
Approximately 1 week after initial dose of vaccine, I developed left axillary adenopathy.  The following day, I experienced mild itching at the injection site and noticed minor swelling.  The entire deltoid region developed diffuse erythema.  Motrin relieved the pain and over the ensuing 3 days, all symptoms resolved.
Migraines since about 6 months ago; vertigo since about 6 months ago/ vertigo since before the booster; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (Migraines since about 6 months ago) and VERTIGO (vertigo since about 6 months ago/ vertigo since before the booster) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B214) for COVID-19 vaccination.     Concurrent medical conditions included Migraine.    On 19-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, the patient experienced MIGRAINE (Migraines since about 6 months ago) and VERTIGO (vertigo since about 6 months ago/ vertigo since before the booster). At the time of the report, MIGRAINE (Migraines since about 6 months ago) and VERTIGO (vertigo since about 6 months ago/ vertigo since before the booster) outcome was unknown.            NO Concomitant drug reported. NO Treatment drug reported.   This case was linked to MOD-2021-404999 (Patient Link).
24 hours after vaccine administration, severe nausea, dizzyness, and headache began that lasted 24 hours. (slept for 24 hours) continuing redness, pain, and warmth at vaccination site.
Pt recvd vax in the AM reports the by late PM (4PM) felt onset of h/a, aching of site of inject, 1-2 hrs of nausea; aching spread to elbows & shoulder; site of inject has 2mm induration; no redness; no edema;
i order for one and given for a 14 years old / administered an adult vaccine to a pediatric patient; administered an adult vaccine to a pediatric patient; This case was reported by a other health professional and described the occurrence of adult product administered to child in a 14-year-old patient who received HAV (Havrix adult) for prophylaxis.   On an unknown date, the patient received Havrix adult. On an unknown date, unknown after receiving Havrix adult, the patient experienced adult product administered to child and overdose. On an unknown date, the outcome of the adult product administered to child and overdose were unknown.  Additional details were provided are as follows: Reporter reported that he had placed an order for the vaccine Havrix for pediatric. Havrix adult was accidentally given to 14 years old patient which led to adult product administered to child and overdose. No further details were provided.
Myalgias, arthralgias, HA, no fever resolved 2 days following injection. Also developed erythema, redness, edema around injection site which at day 8 extended 10 cm distal to injection site. No evidence of cellulitis.
Chills / sweating : 4/7 all night into 4/8  Fatigue : 4/7-4/9 Nausea: 4/8-4/9 Muscle / body ache: 4/7-4/9
LOCALIZED REDNESS, SWELLING, LASTING THRU 4/24/2010, PT APPLIED MOIST COMPRESSES WITH IMPROVEMENT OF SYMPTOMS SWELLING TO RIGHT ARM
Patient passed out after 4th vaccine administration , which was Trumenba. patient was out for less than 5 seconds, came to thinking he was dreaming. Patient remained in room with no other issues.
Stye/swollen upper eyelid of right eye with white discharge, sharp/burning intermittent pain in right calf muscle. Warm compress for eye. No treatment for calf pain. Eyelid improvement, however still a little swollen and red at this point. Right calf pain has not recurred in past two days.
a temperature excursion MMR II had been administered; no further adverse event (AE); This spontaneous report as received from a registered nurse referring to a currently would be 4-year-old patient of unknown gender. The patient's pertinent medical history, concomitant drugs and drug allergies were not reported.  On an unknown date, the patient was vaccinated with improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (lot # S020160, expiration date was 30-JUN-2021, dose was 1 injection, route was not reported) for prophylaxis. The temperature excursion of this vaccine was above 8 degree Celsius (C) (9.0 C) for 26 minutes without any previous temperature excursion. The digital data logger was involved. No further adverse event (AE).
Aft immediately upon completion of administrating vaccines pt stated 'what a bad feeling I have' and was observed by this nurse to have a fainting spell with clonic movements. Regained alertness within 30 seconds. Pt was seated in chair at time of occurrence. Legs were elevated. Juice given. Pt also vomited small amount. Pt was assessed by nurse practitioner. Respirations normal. Pt was monitored.
Severe flair up of genital herpes (much worse than original 38 years ago. It's better now but still fighting the rash EVERY day. Whizzing in my chest. When I lay down I can hear gurgling in my chest. Severe migraines. Vertigo. I still suffer from all of these as of today.
1 3/4 yrs p/initial series of vax employee found to be negative to Anti HBs waning immunity; Given 3 doses 9DEC99, 5JAN89, 16JUN89;
No adverse effects reported; Patient was vaccinated with a dose of improperly stored GARDASIL 9; This spontaneous report was received from a medical assistant concerning to a patient of unknown age and gender. The patient medical history, concurrent conditions and concomitant medications were not reported.  On an unknown date, the patient was vaccinated with improperly stored HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) lot #R032766, expiration date on for prophylaxis (strength, dose and frequency were not reported). The temperature of storage and time frame of the excursion were above 47°F (92.3° F) for 13 hours 11 minutes and above 47°F (73°F) for 9 hours. There was a digital data logger involved, but there was no previous temperature excursion.   No adverse effect was reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-US-009507513-1907USA007468: US-US-009507513-1907USA007439: US-US-009507513-1907USA005368: US-US-009507513-1907USA005362: US-US-009507513-1907USA010550: US-US-009507513-1907USA010551: US-US-009507513-1907USA010552: US-US-009507513-1907USA010554: US-US-009507513-1907USA010555: US-US-009507513-1907USA010556: US-US-009507513-1907USA010557: US-US-009507513-1907USA010558:
(After receiving the vaccine) was dick that evening/ (After receiving the vaccine) was dick the next day; Like the flu; Fever; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL ((After receiving the vaccine) was dick that evening/ (After receiving the vaccine) was dick the next day), INFLUENZA LIKE ILLNESS (Like the flu) and PYREXIA (Fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL ((After receiving the vaccine) was dick that evening/ (After receiving the vaccine) was dick the next day), INFLUENZA LIKE ILLNESS (Like the flu) and PYREXIA (Fever). At the time of the report, FEELING ABNORMAL ((After receiving the vaccine) was dick that evening/ (After receiving the vaccine) was dick the next day), INFLUENZA LIKE ILLNESS (Like the flu) and PYREXIA (Fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101 (High) Other.         No relevant concomitant medications were reported. No treatment information was provided.  Action taken with mRNA-1273 in response to events was not applicable.
soreness in my arm; body aches; fever of 101; chills; headaches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness in my arm), PAIN (body aches), PYREXIA (fever of 101), CHILLS (chills) and HEADACHE (headaches) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Apr-2021, the patient experienced PAIN IN EXTREMITY (soreness in my arm), PAIN (body aches), PYREXIA (fever of 101), CHILLS (chills) and HEADACHE (headaches). At the time of the report, PAIN IN EXTREMITY (soreness in my arm), PAIN (body aches), PYREXIA (fever of 101), CHILLS (chills) and HEADACHE (headaches) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Apr-2021, Body temperature: 101 (High) 101 fever.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The consumer tried to control her temperature with cold cloths, ibuprofen, and has been drinking water and Gatorade.
pt recv vax 2DEC97 & 10DEC97 pt devel a rash consisting of approx 100 lesions;
The patient got the flu; Chills; Body ache; c; Fever; Nausea; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 04-Dec-2020.  This case involves a patient of unknown demographics who got Flu (Influenza), Chills (Chills), Body ache (Pain), Headache (Headache), Fever (Pyrexia) and Nausea (Nausea), while the patient received Influenza Vaccine.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication was unknown.  On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date, the patient stated that he/she got Flu (Influenza), Chills (Chills), Body ache (Pain), Headache (Headache), Fever (Pyrexia) and Nausea (Nausea) for a week or ten days with the INFLUENZA VACCINE afterward. It was reported that patient had three shots of flu and all he times he/she got flu. It was also reported that the patient was healthy before the flu shot and he/she would not get it.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown, at the time of reporting.  There will be no information available on the batch number for this case.
27 hours post vaccine - fever, fatigue, lymphadenopathy   in arm pit and breast tenderness in the same side as the injection was given.